You've had the bloodwork. Your doctor glances at the results and says everything looks normal — glucose fine, cholesterol acceptable, nothing flagged. And yet the fatigue, the stubborn midsection weight, the sense that your metabolism has shifted are all still there. If "normal labs" and "something's clearly changed" seem to contradict each other, they may not be. The issue is often what a standard panel is designed to catch — and what it isn't.
This is a place where honesty matters more than a tidy story, because there's a lot of oversimplified messaging in this space. So here's the careful version.
What a standard metabolic panel actually measures
When most people get "metabolic" bloodwork, the blood-sugar picture comes down to two markers: fasting glucose and HbA1c (a three-month average of blood sugar). Both are good tests. But both share a limitation that matters enormously in midlife: they measure the outcome — blood sugar — rather than the effort your body is expending to keep that blood sugar normal.
That distinction is the whole point. For years, your body can compensate for developing metabolic dysfunction by simply making more insulin. Glucose stays in range not because everything is fine, but because your pancreas is working progressively harder to keep it there.
Why glucose is a late signal
Here's the mechanism, and it's well established in the clinical literature. As tissues become less responsive to insulin — insulin resistance — the pancreas compensates by secreting more of it. This keeps blood glucose normal for a long time. Glucose only rises once that compensation begins to fail, when the pancreas can no longer keep up with demand. [1]
The timescale is the striking part: insulin resistance is thought to precede the development of type 2 diabetes by roughly 10 to 15 years. [1] That means a person can have meaningful, developing metabolic dysfunction for a decade or more while their fasting glucose and HbA1c still read "normal" — because those markers, by design, move late in the process. The normal result isn't wrong. It's just answering a different question than the one you're asking.
Why this intersects perimenopause specifically
This is where midlife makes the gap matter. As we cover in our articles on perimenopausal metabolism, declining estrogen nudges many women toward reduced insulin sensitivity during exactly the same years — the forties and early fifties — when the compensation-masking effect is in full swing. So the very window where metabolic change is most likely to be developing is also the window where standard glucose markers are least likely to reveal it. A woman can feel the shift clearly and be told, accurately by the test's own logic, that her numbers are fine.
The honest part: what's supported and what's oversold
Because this topic attracts a lot of confident marketing, here's the careful line between what's well-established and what isn't.
Well-supported: Fasting glucose and HbA1c become abnormal relatively late, and normal values don't rule out earlier insulin resistance. Additional markers — fasting insulin (not just glucose), and calculated indices that pair insulin with glucose — can reflect that earlier stage. This is grounded in the physiology, not fringe.
Contested or oversold: You'll see specific "optimal range" cutoffs presented as settled fact, often by companies selling the tests. They aren't settled. In fact, clinical reference literature is blunt on this point: measures of insulin resistance have not been integrated into clinical guidelines, and there is no single, generally accepted test for insulin resistance — the clinical definition itself remains, in the literature's own word, elusive. Expert opinion genuinely differs on where thresholds should sit, and there's even active scientific debate about the underlying sequence of events (whether insulin resistance or high insulin comes first). So anyone presenting a single magic number as definitive is overstating the state of the science.
The reasonable takeaway sits between dismissal and hype: if your symptoms and your "normal" labs don't match, that mismatch is worth a real conversation — not a reason to panic, and not something a lab-selling website can resolve for you.
Where care fits
What this actually points to is the value of a provider who looks past a single in-range number — who takes midlife symptoms seriously, considers whether a fuller metabolic picture is warranted, and interprets results in the context of the whole person rather than a green checkmark on one line.
That's the model Cypress is built around: care designed for the perimenopausal body, with a licensed provider reviewing you first. If you want to understand what that review involves, you can learn how provider-reviewed care works.